Utah Medical Products, Inc.UTMDNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+40.0%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+40.0%/yr
vs -12.3%/yr prior
Acceleration
+52.3pp
Accelerating
Percentile
P95
Near historical high
vs 3Y Ago
2.7x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 26.95% |
| Q3 2025 | 23.70% |
| Q2 2025 | -12.90% |
| Q1 2025 | 28.10% |
| Q4 2024 | -29.65% |
| Q3 2024 | -32.55% |
| Q2 2024 | -4.14% |
| Q1 2024 | 82.19% |
| Q4 2023 | 5.80% |
| Q3 2023 | 3.76% |
| Q2 2023 | -7.64% |
| Q1 2023 | 17.07% |
| Q4 2022 | 9.82% |
| Q3 2022 | -17.04% |
| Q2 2022 | 9.76% |
| Q1 2022 | -12.77% |
| Q4 2021 | 11.02% |
| Q3 2021 | -0.78% |
| Q2 2021 | -1.54% |
| Q1 2021 | 17.12% |
| Q4 2020 | -11.20% |
| Q3 2020 | 7.76% |
| Q2 2020 | -14.07% |
| Q1 2020 | 7.14% |
| Q4 2019 | -3.08% |
| Q3 2019 | 15.04% |
| Q2 2019 | -1.74% |
| Q1 2019 | -0.86% |
| Q4 2018 | 7.41% |
| Q3 2018 | -7.69% |
| Q2 2018 | 3.54% |
| Q1 2018 | 6.60% |
| Q4 2017 | 2.91% |
| Q3 2017 | -13.45% |
| Q2 2017 | 0.85% |
| Q1 2017 | 6.31% |
| Q4 2016 | -17.78% |
| Q3 2016 | 13.45% |
| Q2 2016 | 8.18% |
| Q1 2016 | -5.17% |